Is RARE or REGN more undervalued in 2026?

CirclFi compares Ultragenyx Pharmaceutical Inc. (RARE) and Regeneron Pharmaceuticals, Inc. (REGN) using 13 institutional-grade valuation models. RARE has a Quality of Company score of 6.3/10 while REGN scores 9.6/10.

Which is a better buy — RARE or REGN?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do RARE and REGN valuations compare?

RARE at $23.26 and REGN at $621.52 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

RARE vs REGN Valuation Comparison 2026 — Intrinsic Value Analysis

RARE

Biotechnology

Ultragenyx Pharmaceutical Inc.

Quality

6.3

out of 10

Value Trap

SAFE

Price

$23.26

Last close

Models

12/13

Active

REGN

Biotechnology

Regeneron Pharmaceuticals, Inc.

Quality

9.6

out of 10

Value Trap

SAFE

Price

$621.52

Last close

Models

13/13

Active

Model-by-Model Comparison

Model	Type	RARE Fair Value	RARE Upside	REGN Fair Value	REGN Upside
Bayesian DCF	Intrinsic	$7.84	-66.3%	$613.30	-1.3%
Earnings Power Value	Intrinsic	$16.16	-32.9%	$256.47	-58.7%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for RARE vs REGN — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

RARE vs REGN — Which Stock Is More Undervalued?

REGN scores higher with a 9.6/10 quality rating vs RARE's 6.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Ultragenyx Pharmaceutical Inc. (RARE) and Regeneron Pharmaceuticals, Inc. (REGN) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

RARE currently trades at $23.26 with a QOC of 6.3/10, while REGN trades at $621.52 with a QOC of 9.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).